Reading time: 5 minutes Varshit Dusad A cancer diagnosis is generally perceived to be a death sentence. With millions of people dying of cancer every year, this does not seem to be at all outrageous. However, researchers all over the world, in academia and industry alike, have been relentlessly pursuing novel therapies and drugs to... Continue Reading →
Reading time: 4 minutes Manisit Das In the past, we have discussed checkpoint inhibitors - therapies that block communication between cancer and immune cells, preventing cancer cells from evading the immune system. Dr. James Allison and Dr. Tasuku Honjo, who won the Nobel Prize in Medicine in 2018 for their pioneering work in cancer immunotherapy... Continue Reading →
Reading time: 3 minutes Alex S. Woodell A warm breeze whips by as you notice a peculiar set of clouds forming in the distance. These cumulus clouds are tall with bumpy protrusions that flatten out near the top to form a silhouette of a giant anvil. As condensation builds in these behemoths, the bright sunlight... Continue Reading →
Reading time: 4 minutes Sara Musetti Cancer immunotherapy has been a very hot topic here at OncoBites (because it’s a hot topic right now among cancer researchers too), but let me be super clear ⎯ it is COMPLICATED. Your immune system is balanced extremely delicately to avoid sending you into shock each time you are... Continue Reading →
Reading time: 4 minutes Alex S. Woodell Marathon runners are an interesting breed. In order to complete the grueling 26.2 mile circuit, they must push their mental and physical boundaries to the limit. Seasoned runners possess great strength, focus, resilience, and determination. Each of these qualities is a testament to the intense training schedules they... Continue Reading →
Reading time: 6 minutes Payal Yokota Despite the advent and access to a variety of targeted immunotherapy approaches, the current paradigm for solid tumors still remains if you can cut it out – you do! Depending on the grade of tumor and degree of metastasis, there’s a substantial risk of tumor resurgence. In those cases,... Continue Reading →
Reading time: 4 minutes Bekah Schulz Many people are excited about checkpoint inhibitors in cancer immunotherapy. In fact, the 2018 Nobel Prize in medicine was awarded for the development of two checkpoint inhibitors PD-1/L1 (Opdivo/Keytruda) and CTLA-4 (Yervoy). However, cancer immunotherapy is not a new concept. In fact, in 1986, recombinant interferon (IFN) alpha was... Continue Reading →
OncoBites 